enrolment – Page 16 – Communicable Diseases Research

Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-292022-10-29
Journal: Trials [Category] Coronavirus, SARS,

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 A-a gradient acute lung injury acute respiratory distress addition allergic reaction alveolar macrophage alveolar pressure antiviral immunity Antwerp ARDS Belgium blinded Breastfeeding Bruges carbonate clinical clinician Confirmed COVID-19 infection control group Controlled trial COVID-19 COVID-19 pandemic defined Delta dissemination Effect element enrolled enrolment EudraCT ferritin level Ghent GM-CSF granulocyte-macrophage colony-stimulating factor High dose hospital Hypothesis hypoxic failure hypoxic respiratory failure Immune homeostasis inflammatory monocyte Inhaled Intervention intravenous invasive mechanical IWRS system leukine® lung malignancy mechanical ventilation mechanical ventilator Methylprednisolone number objective Open-label outcome oxygen Oxygenation paO2/fiO2 parameters Partial participant Participants Patient PF ratio pregnant primary endpoint progression of disease promote Protein protocol randomised randomised controlled trial randomization Randomized reached receive recruitment Registered Repair mechanisms replaced Respiratory failure Roeselare Sample size sargramostim SpO2 standard care Standard of care status Study protocol supplemental oxygen Support syndrome therapy treat Treatment Trial university ventilatory support Version website were excluded White blood cell
[DOI] 10.1186/s13063-020-04451-7 PMC 바로가기 [Article Type] Letter

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 age analogue anticipated assigned Asymptomatic blinded bpm Characteristics clinical trial comparator components Contact Controlled trial coronavirus disease COVID-19 COVID-19 symptom COVID19 Date deficiency develop Diabetes Mellitus Diagnosis disease dissemination dose double-blind drug Efficacy Efficiency eight element enrolled enrolment EU Clinical Trial evaluate evaluate the effect exclusion criteria experimental arm female participant Final Glucose haloperidol healthcare healthcare worker Healthcare workers hematological Hemodialysis hepatitis B Hereditary high risk history HIV HIV infection hospital hypersensitivity IgM/IgG immune immunosuppressive incidence Inclusion Infection Inflammatory cytokine Intervention less lymphopenia male melatonin men and women multicenter myasthenia gravis number objective outcome participant Patient PCR Placebo polymerase chain post-symptom onset Premenopausal Prevent prophylactic treatment Prophylaxis protocol Ramón randomisation randomised randomised controlled trial randomization Randomized Rapid test receiving recruited renal failure Research Retinitis rheumatoid arthritis risk RT-PCR Sample size SARS-CoV 2 SARS-CoV-2 SARS-COV-2 infection SAS version 9.4 secondary sequence Seroconversion severe COVID-19 severity of COVID-19 Sex Spain Spanish statistical status stratified study drug Study protocol symptomatic infection symptomatic SARS-CoV-2 infection Treatment Trial two-arm parallel ulcerative colitis understanding urinary pregnancy test Vasculitis website weight women
[DOI] 10.1186/s13063-020-04436-6 PMC 바로가기 [Article Type] Letter

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Research article

Published on 2020-05-282022-10-05
Journal: Lancet (London, England) [Category] SARS, 유전자 메커니즘, 치료법,

[키워드] active cancer acute respiratory syndrome age all-cause mortality analysed anticancer appear assumption Cancer cancer centre cancer patient cardiovascular disease Chemotherapy Clinical diagnosis Comorbidities Comorbidity coronavirus COVID-19 COVID-19 disease COVID-19 disease course COVID-19 mortality demographic characteristics diagnosis of cancer discharge driven by Effect eligible enrolment Evidence excluded finding funding Gender had no hormonal therapy hospital Hospital admission hypertension identify Immunotherapy increased risk individual male Mild monitoring Mortality multicentre no significant effect Odds ratio outcome pandemic Patient patients died Patients with cancer positive positive RT-PCR presenting primary endpoint prospective cohort study prospective observational study radiological Radiotherapy receiving risk of death RT-PCR assay significant effect significantly Support symptomatic targeted therapy tested the patient throat swab Treatment university University of Oxford
[DOI] 10.1016/S0140-6736(20)31173-9 [Article Type] Research article

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial

중증 COVID-19 성인 환자에 대한 정맥 주사 렘데시비르의 효능 및 안전성 평가: 무작위 배정, 이중 맹검, 위약 대조, 다기관 임상 3상 연구 프로토콜

Study Protocol

Published on 2020-05-242022-09-10
Journal: Trials [Category] MERS, SARS, 비임상,

[키워드] Administered Administrative information Adult patients Antiviral assigned asymptomatic infection breath category caused China Clinical efficacy Clinical improvement clinical manifestation clinical manifestations clinical status clinical trial concern conducted coronavirus disease Coronavirus disease 2019 Coronavirus infections Coronaviruses COVID-19 COVID-19 virus death defined discharge double-blind Efficacy Efficacy and safety Emergency enrolment event futility GS-5734 Health Organization highly pathogenic hospital in vitro in vivo experiments include Infection inhibitory inhibitory effect Inhibitory effects interim analysis Intravenous remdesivir intravenously laboratory-confirmed MERS-CoV Mild multicentre nucleoside Ordinal Scale Patient Phase 3 Placebo placebo-controlled placebo-controlled trial Pneumonia primary endpoint protocol Public public health emergency randomization Randomized Randomly Remdesivir reported required Respiratory failure SARS-CoV SARS-CoV-2 virus severe COVID-19 severe pneumonia severe viral pneumonia Spread Standard Study protocol Symptoms Treatment Trial Trial registration upper respiratory symptoms Viral Viral pneumonia virus infection World Health Organization Wuhan
[DOI] 10.1186/s13063-020-04352-9 PMC 바로가기 [Article Type] Study Protocol

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

중증 COVID-19 성인에 대한 렘데시비르: 무작위, 이중 맹검, 위약 대조, 다기관 시험

Randomized Controlled Trial

Published on 2020-05-162022-09-11
Journal: Lancet (London, England) [Category] SARS, 비임상,

[키워드] Academy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adult patients Adverse adverse event adverse events Analysis animal models antiviral drug arterial oxygen partial pressure assigned Beijing breath China Chinese clinical benefits Clinical improvement clinical status concomitant use confirmation coronavirus coronavirus disease Coronavirus disease 2019 Corticosteroids COVID-19 defined development discharged double-blind effective Eligible patients Emergency enrolled enrolment event faster followed by fractional inspired oxygen GS-5734 hazard ratio hospital human coronaviruses in vitro inhibit inhibitory effect Inhibitory effects intention-to-treat interferons Intravenous remdesivir ITT ITT population laboratory-confirmed SARS-CoV-2 infection less Lopinavir Lopinavir-ritonavir Medical Science Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus multicentre nucleoside one patient Ordinal Scale oxygen oxygen partial pressure oxygen saturation partial pressure pathogenic Patient Placebo placebo group placebo recipients placebo-controlled Pneumonia primary analysis primary endpoint Program randomisation randomised Randomly receiving recipient reduction in Registered Remdesivir reported research and development respiratory respiratory syndrome coronavirus Ritonavir room air safety analysis SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication Science severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 statistically significant symptom duration symptom onset technology the placebo group those receiving placebo treated Treatment treatment group Trial Volume was done
[DOI] 10.1016/S0140-6736(20)31022-9 PMC 바로가기 [Article Type] Randomized Controlled Trial

Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial

HIV에 감염된 임산부에서 3가 비활성화 인플루엔자 백신의 다양한 투여 일정의 면역원성과 안전성: 무작위 대조 시험

Article

Published on 2020-01-032022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] age All participants analysed Antenatal Antibody Response assigned Birth clinics completion computer-generated Controlled trial dose dosing schedule double-blind eligible ENhance enrolled enrolment estimated gestational age except for Final finding foundation Frequency funding gestational age greater group Group allocation HIV immunogenic immunogenicity Immunogenicity analyses immunogenicity analysis inactivated induce Infant Infants Influenza influenza vaccine Local Melinda Gate Melinda Gates mother Neonates Newborn newborn infants outcome participant pregnant women protective antibodies Protective antibody randomisation list randomised randomised controlled trial Randomly reaction receive recipient recipients recruited regimen Registered Safety Seasonal influenza seroconversion rate seroconversion rates Seven significantly higher single dose Single-dose South Africa Standard-dose strain Strains systemic reactions the vaccine three groups transfer trivalent Vaccine vaccine dose were measured with HIV women
[DOI] 10.1016/S2352-3018(19)30322-4 PMC 바로가기 [Article Type] Article

Rationale and design of the “Tocilizumab in patients with moderate to severe COVID-19: an open-label multicentre randomized controlled” trial (TOCIBRAS)

"중등도에서 중증의 COVID-19 환자에 대한 토실리주맙: 공개 라벨 다기관 무작위 통제" 시험(TOCIBRAS)의 근거 및 설계

Original Article

Published on 2020-01-012022-08-13
Journal: Revista Brasileira de Terapia Intensiva [Category] 임상,

[키워드] 7-point ordinal scale adjusted age and sex alleviate Analysis anti-inflammatory therapies Anti-inflammatory therapy applied approved Brazil C reactive protein Clinical outcome clinical outcomes clinical status combating consequence Coronavírus COVID-19 COVID-19 patient COVID-19 patients criteria D-dimer disease severity dissemination enrolment ethical committee Ethics ferritin IMPROVE inflammatory cascade inflammatory mediator Inflammatory response inhibiting institutional review board institutional review boards interleukin-6 International Lactate lactate dehydrogenase limit Local mediator moderate to severe multicentre National Odds ratio Open-label ordinal logistic regression Ordinal Scale outcome patients patients with COVID-19 patients with moderate primary endpoint Pro-inflammatory marker pro-inflammatory markers protocol Randomized Randomized controlled trial rationale required severe COVID-19 severity Standard of care Stratification Study protocol the disease The TOCIBRAS protocol TOCIBRAS Tocilizumab Tocilizumabe Trial trial testing variable
[DOI] 10.5935/0103-507X.20200060 PMC 바로가기 [Article Type] Original Article

Economic incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial

짐바브웨 청소년의 HIV 검사에 대한 경제적 인센티브: 무작위 대조 시험

Article

Published on 2017-11-202022-09-06
Journal: The Lancet. HIV [Category] Communicable Disease,

[키워드] 95% CI adjusted odds ratio Adults adverse event adverse events African Analysis Antiretroviral therapy assigned assistant blinded Care Caregivers children clinical Community Consent Controlled trial Coverage Effect eligible enrolled enrolment finding fixed funding group had no health-care HIV HIV infection HIV testing household Households Intention intention to treat investigated Local Logistic regression much lower not blinded number of children Older outcome Pan Pan African Clinical Trials Registry participant Prevalence prevention service Primary outcome proportion provided random effect randomised controlled trial Randomly receive Registered registry repeated reported Research statistician tested Trial Wellcome Trust Zimbabwe
[DOI] 10.1016/S2352-3018(17)30176-5 PMC 바로가기 [Article Type] Article

Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial

HIV-1에 감염된 건강한 성인에서 후보 결핵 백신 MVA85A의 안전성, 면역원성 및 효능: 무작위, 위약 대조, 2상 시험

Articles

Published on 2015-03-012022-09-06
Journal: The Lancet. Respiratory Medicine [Category] Communicable Disease,

[키워드] 1:1 95% CI absence active tuberculosis adverse event Antigen antigen 85A antigen 85A-specific T-cell response antiretroviral Antiretroviral therapy assigned assist baseline baseline CD4 block blocks booster Cape CD4 count CD4 counts Cell clinical defined detect detectable Developing disease double-blind effective Efficacy eligible Eligible participants enrolled enrolment European Evidence evidence of expressing finding first vaccination foundation funding gold greater Group allocation had no healthy HIV-1 HIV-1 infection immunogenic immunogenicity include increased risk Infection injection intradermal injections investigators isoniazid isoniazid prophylaxis Laboratory latent tuberculosis latent tuberculosis infection M tuberculosis Measures Melinda Gate Melinda Gates modified vaccinia virus MVA85A Mycobacterium tuberculosis nine no evidence of Nurses occurred outcome participant partnership peaked per-protocol analysis per-protocol population Phase 2 phase 2 trial Placebo placebo group placebo-controlled positive Potential Prophylaxis protocol QuantiFERON QuantiFERON-TB Gold In-Tube randomisation randomised Randomly receive receiving Registered reported Safe Safety safety analysis second vaccination secondary Secondary outcomes sequence Serious Adverse Event Serious Adverse Events significant increase South Africa stratified subset T-cell Response the placebo group therapy town Treatment Trial Tuberculosis tuberculosis disease tuberculosis vaccine undetectable vaccination Vaccine vaccine efficacy vaccine-induced immune response Viral Viral load Wellcome Trust were assessed
[DOI] 10.1016/S2213-2600(15)00037-5 PMC 바로가기 [Article Type] Articles